Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular Repair

Not Applicable

Active, not recruiting

• Conditions: Vascular Diseases
• Interventions: Device: Implant the XenoSure patch; Procedure: Repair/reconstruction of the diseased vessel; Device: Implant the Vascular-Patch

• Registration Number: NCT03173703
• Lead Sponsor: LeMaitre Vascular

Brief Summary

The purpose of this trial is to collect safety and effectiveness data to support peripheral vascular indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulation in this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.

Detailed Description

The purpose of this trial is to collect safety and effectiveness data to support peripheral vascular indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulation in this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.

144 subjects for peripheral vascular repair, including respective 72 subjects for the trial group and the control group.

Study Timeline

• Study First Submitted: 2017-05-25
• Study First Submitted QC: 2017-05-31
• Study First Posted: 2017-06-02
• Study Start: 2017-07-13
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-07
• Last Update Posted: 2025-03-10
• Primary Completion: 2025-11-15
• Study Completion: 2025-11-15

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

• 1. Any man or woman aged between 18~80 years old 2) The expected lifetime of no less than 12 months 3) The subject can be considered for suturing with XenoSure Biological Patch after the peripheral vascular repair surgery. The subject's targeted arterial diameter is less than 5mm or the arterial incision length is more than 4cm and less than 9cm.

4. Physical conditions and vital signs meet requirements for the surgery. 5) The subjects and/or their guardians sign the written Informed Consent Form.

Exclusion Criteria

1. Patients with severe visceral diseases in heart, liver, kidney, etc.

2. Patients have unstable vital signs and not suitable for the surgery indications

3. Patients need vascular outflow stenting repair in the same location with XenoSure® Biological Patch.

4. Pregnant or lactating women

5. Patients With severe allergic history (especially allergic to bovine materials)

6. Patients with the past medical history of severe immunodeficiency disease

7. The subject has used or plans to use immunomodulatory drugs for more than half a year.

8. The subject with poor blood clotting function is defined as that pre-operative INR or APTT is prolonged over 30% than the reference value without drug intervention, or that blood platelet count is less than 100*10^9/L.

9. The subject has severe kidney disorders or diseases with the estimated glomerular filtration rate [GRF]<30mL/min/1.73m2.

10. The subject's ALT or AST level is 2.5 times higher than the upper normal limit or the subject has active liver disease or icterus.

11. The subject has participated in another clinical study within 3 months or is participating in another clinical study now.

12. The investigator believes that the subject has other reasons unsuitable for inclusion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Test Arm	Repair/reconstruction of the diseased vessel	Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
Test Arm	Implant the XenoSure patch	Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
Control Arm	Repair/reconstruction of the diseased vessel	Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.
Control Arm	Implant the Vascular-Patch	Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.

Primary Outcome Measures

Name	Time	Method
Primary patency measured by ultrasound	6 months	The treated vessel is considered "patent" if the re-narrowing of the ID of the vessel is less than 20% of the ID that measured immediately after procedure. The study is considered achieved its primary endpoint if the primary patency rate of test device is non-inferior to the rate of the comparator device.

Trial Locations

Locations (1)

Hua Shan Hospital; 🇨🇳 Shanghai, Shanghai, China